Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network.
自體顯性多囊腎病患者中 tolvaptan 對腎臟替代療法的有效性:來自 TriNetX 全球合作網絡的回顧性隊列研究。
Ren Fail 2024-10-18
Correction to: Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.
修正:在接受 agalsidase beta 治療的 Fabry 病患者中,腎功能下降及嚴重臨床事件風險的減少:來自 Fabry 註冊的匹配分析。
Clin Kidney J 2024-10-18
Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: a <i>post hoc</i> analysis of phase 3 data using the Skindex-10 questionnaire.
慢性腎病相關的癢感與 difelikefalin 治療的生活品質:使用 Skindex-10 問卷的第三期數據的 <i>事後</i> 分析。
Clin Kidney J 2024-10-18
How low can we go with the dialysate flow? A retrospective study on the safety and adequacy of a water-saving dialysis prescription.
我們可以將透析液流量降低到多低?一項關於節水透析處方的安全性和充分性的回顧性研究。
Clin Kidney J 2024-10-18
Enhancing vascular access planning in CKD: validating the 40% KFRE threshold for predicting ESKD in a French retrospective cohort study.
在慢性腎病中增強血管通路規劃:驗證法國回顧性隊列研究中預測末期腎病的 40% KFRE 閾值。
Clin Kidney J 2024-10-18
Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants.
心房顫動及 CKD G3-G5D 患者使用口服抗凝劑的重大出血風險因素。
Clin Kidney J 2024-10-18